The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults

Abstract Objectives The gold standard for the management of drug‐resistant focal epilepsy (DRE) is resection of epileptogenic zone. However, some patients may not be candidates for resection. Responsive neurostimulation is approved in patients above 18 years of age for such patients. We aimed to inv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ifrah Zawar, Balu Krishnan, Michael Mackow, Andreas Alexopoulos, Dileep Nair, Vineet Punia
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	brain‐responsive neurostimulation epilepsy older adults RNS System Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2d40cb71f83b4c81874df6a485325176
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d40cb71f83b4c81874df6a485325176
record_format	dspace
spelling	oai:doaj.org-article:2d40cb71f83b4c81874df6a4853251762021-12-01T06:09:19ZThe Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults2470-923910.1002/epi4.12541https://doaj.org/article/2d40cb71f83b4c81874df6a4853251762021-12-01T00:00:00Zhttps://doi.org/10.1002/epi4.12541https://doaj.org/toc/2470-9239Abstract Objectives The gold standard for the management of drug‐resistant focal epilepsy (DRE) is resection of epileptogenic zone. However, some patients may not be candidates for resection. Responsive neurostimulation is approved in patients above 18 years of age for such patients. We aimed to investigate whether RNS outcomes and safety varied based on age. Methods We performed a single‐center retrospective cohort study of patients with DRE who were treated with RNS between May 2008 and February 2020. We included patients who had been implanted with RNS for >6 months (N = 55), dividing them into older (N = 11) and younger adults (N = 44) depending on implantation age (≥50 and <50 years, respectively). Results Mean age at implantation in older adults was 54.9 ± 3.5 years. Seizure onset age, epilepsy duration, and comorbidities were significantly higher in older adults ( P < .01). Stimulation parameters, treatment duration, and median seizure frequency reduction (76% in older vs 50% in younger adults) were statistically comparable between the two cohorts. Posttreatment, antiseizure medication burden was significantly decreased in older compared with younger adults (P = .048). Postoperative and delayed adverse events among older adults were mild. Compared with three younger adults, none of the older adults required device explantation due to surgical site infection.Conclusion Our study suggests that older adults treated with the RNS System achieve seizure outcomes comparable to younger adults with the additional benefit of a significant postimplantation medication reduction. With efficacy and safety similar to younger adults, brain‐responsive neurostimulation was well‐tolerated in older adults.Ifrah ZawarBalu KrishnanMichael MackowAndreas AlexopoulosDileep NairVineet PuniaWileyarticlebrain‐responsive neurostimulationepilepsyolder adultsRNS SystemNeurology. Diseases of the nervous systemRC346-429ENEpilepsia Open, Vol 6, Iss 4, Pp 781-787 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain‐responsive neurostimulation epilepsy older adults RNS System Neurology. Diseases of the nervous system RC346-429
spellingShingle	brain‐responsive neurostimulation epilepsy older adults RNS System Neurology. Diseases of the nervous system RC346-429 Ifrah Zawar Balu Krishnan Michael Mackow Andreas Alexopoulos Dileep Nair Vineet Punia The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
description	Abstract Objectives The gold standard for the management of drug‐resistant focal epilepsy (DRE) is resection of epileptogenic zone. However, some patients may not be candidates for resection. Responsive neurostimulation is approved in patients above 18 years of age for such patients. We aimed to investigate whether RNS outcomes and safety varied based on age. Methods We performed a single‐center retrospective cohort study of patients with DRE who were treated with RNS between May 2008 and February 2020. We included patients who had been implanted with RNS for >6 months (N = 55), dividing them into older (N = 11) and younger adults (N = 44) depending on implantation age (≥50 and <50 years, respectively). Results Mean age at implantation in older adults was 54.9 ± 3.5 years. Seizure onset age, epilepsy duration, and comorbidities were significantly higher in older adults ( P < .01). Stimulation parameters, treatment duration, and median seizure frequency reduction (76% in older vs 50% in younger adults) were statistically comparable between the two cohorts. Posttreatment, antiseizure medication burden was significantly decreased in older compared with younger adults (P = .048). Postoperative and delayed adverse events among older adults were mild. Compared with three younger adults, none of the older adults required device explantation due to surgical site infection.Conclusion Our study suggests that older adults treated with the RNS System achieve seizure outcomes comparable to younger adults with the additional benefit of a significant postimplantation medication reduction. With efficacy and safety similar to younger adults, brain‐responsive neurostimulation was well‐tolerated in older adults.
format	article
author	Ifrah Zawar Balu Krishnan Michael Mackow Andreas Alexopoulos Dileep Nair Vineet Punia
author_facet	Ifrah Zawar Balu Krishnan Michael Mackow Andreas Alexopoulos Dileep Nair Vineet Punia
author_sort	Ifrah Zawar
title	The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
title_short	The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
title_full	The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
title_fullStr	The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
title_full_unstemmed	The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults
title_sort	efficacy, safety, and outcomes of brain‐responsive neurostimulation (rns® system) therapy in older adults
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/2d40cb71f83b4c81874df6a485325176
work_keys_str_mv	AT ifrahzawar theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT balukrishnan theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT michaelmackow theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT andreasalexopoulos theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT dileepnair theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT vineetpunia theefficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT ifrahzawar efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT balukrishnan efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT michaelmackow efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT andreasalexopoulos efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT dileepnair efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults AT vineetpunia efficacysafetyandoutcomesofbrainresponsiveneurostimulationrnssystemtherapyinolderadults
_version_	1718405465379962880

The Efficacy, Safety, and Outcomes of Brain‐responsive Neurostimulation (RNS® System) therapy in older adults

Ejemplares similares